SCHEDULE: Trails Edge Capital Discloses 5.1% Stake in Neurogene Inc.
Beneficial Ownership Report
Trails Edge Capital Partners, LP, along with its affiliates, has reported a 5.1% beneficial ownership stake in Neurogene Inc.'s common stock.
Summary
- Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai have jointly filed a Schedule 13G.
- The reporting persons collectively beneficially own 785,000 shares of Neurogene Inc. Common Stock.
- This ownership represents 5.1% of the outstanding shares of Neurogene Inc.
- The ownership percentage is based on 15,489,800 shares reported as issued and outstanding as of November 11, 2025, in Neurogene Inc.'s Form 10-Q.
- Trails Edge Capital Partners, LP is the investment manager to Trails Edge Biotechnology Master Fund, LP.
- Ortav Yehudai is the Chief Investment Officer of Trails Edge Capital Partners, LP and exercises voting and investment discretion over these securities.
- The securities were not acquired for the purpose of changing or influencing the control of Neurogene Inc., other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory report.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates an institutional investor's significant stake in Neurogene Inc., a biotechnology company. Such disclosures can signal investor confidence or strategic positioning within the specialized biotech sector, which often sees substantial institutional investment due to its high-risk, high-reward nature.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may be viewed positively by existing shareholders as it indicates institutional interest and potential confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2025-11-11 | Date as of which 15,489,800 shares were reported as issued and outstanding in Neurogene Inc.'s Form 10-Q. |
| 2025-11-13 | Date Neurogene Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-12-08 | Date of event which requires the filing of this statement (Event Date). |
| 2025-12-15 | Date the Schedule 13G was signed and filed. |
Keywords
Neurogene Inc., Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, Ortav Yehudai, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.